Tagomics Partners with Agilent Technologies to Revolutionize Multiomic Biomarker Discovery

Bio-Techne Partners with Leader Life Sciences to Expand in the GCC Region

Owkin and Proscia Partner to Revolutionize MSI Testing for Colorectal Cancer with AI-Powered Solutions

Telix Expands Theranostic Pipeline with FAP-Targeting Radiopharmaceuticals

Alamar Biosciences and The Michael J. Fox Foundation Partner to Advance Parkinson’s Disease Biomarker Discovery

Stilla Technologies Partners with Source BioScience to Advance Genomics in the UK and Ireland

Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

AbbVie’s ELAHERE® Approved in the EU for Platinum-Resistant Ovarian Cancer

AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® in NSCLC

Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

Home
/
med-marvels
/
details

CAR T-cell Therapy at Narayana Health City Shows Remarkable Success in Cancer Treatment

NextEdge Admin

25 May 2024

3 min 21 sec

Narayana Health City in Bangalore has achieved a breakthrough in cancer treatment through the successful application of CAR T-cell therapy, signifying a significant advancement in the battle against cancer. Developed by IMMUNEEL in Bangalore, this state-of-the-art immunotherapy modifies a patient’s T-cells to enhance their ability to identify and combat cancerous cells.

CAR T-cell therapy, also referred to as Chimeric Antigen Receptor T-cell therapy, has demonstrated remarkable effectiveness in addressing specific blood cancers such as leukemia and lymphoma. The procedure involves the genetic modification of T-cells to specifically target and eradicate cancer cells.

Dr. Sharat Damodar, Senior Consultant Haematologist and Head of Adult BMT at Narayana Health City, remarked, “CAR T-Cell therapy has revolutionized cancer treatment by providing a lifeline to patients who have exhausted conventional options.” He highlighted a case illustrating the therapy’s potential to induce lasting remission in relapsed lymphoma.

The recent approval of CAR T-cell therapy by the Drug Controller General of India (DCGI) for commercial use is a significant milestone for patients grappling with relapsed and refractory cancers. Hamza Khan, a 42-year-old resident of Bangalore, became the inaugural patient in South India to undergo this groundbreaking treatment for relapsed follicular lymphoma.

Hamza’s cancer journey commenced during the COVID-19 pandemic in 2020. Despite undergoing multiple chemotherapy rounds and rituximab maintenance, his cancer relapsed in February 2022, leading to a dire prognosis. Standard treatments, including chemotherapy and autologous stem cell transplant, proved futile, exacerbated by a severe COVID-19 infection.

Selected for CAR T-cell therapy in September 2022, Hamza underwent the procedure under the care of Dr. Sharat Damodar, with successful administration in November 2022. Experiencing minimal side effects, Hamza achieved remission, surpassing the significant milestone of one-year post-treatment without relapse.

Narayana Health City continues to lead the charge in such advancements, ensuring that cutting-edge treatment options are accessible within India. The hospital’s Facility Director expressed immense pride in the strides made in cancer treatment, emphasizing their commitment to providing the best care and hope to patients through innovative therapies like CAR T-cell therapy.